<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36678">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01716221</url>
  </required_header>
  <id_info>
    <org_study_id>11-1141</org_study_id>
    <nct_id>NCT01716221</nct_id>
  </id_info>
  <brief_title>An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to document the clinical effects of bupropion and citalopram in
      a single subject with Friedreich Ataxia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>International Cooperative Ataxia Rating Scale (ICARS)</measure>
    <time_frame>Change from Baseline at 5, 10, 15, and 20 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Friedreich Ataxia Rating Scale (FARS)</measure>
    <time_frame>Change from Baseline at 5, 10, 15, and 20 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of FARS and ICARS</measure>
    <time_frame>Baseline and weeks 5, 10, 15, and 20 scales</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Hamilton Depression Rating Scale</measure>
    <time_frame>Baseline and at 5, 10, 15, and 20 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Friedreich Ataxia</condition>
  <arm_group>
    <arm_group_label>Bupropion &amp; Citalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg Bupropion &amp; 20mg Citalopram taken orally one time per day or 100mg Bupropion &amp; 10mg Citalopram taken orally one time per day or 50mg Bupropion &amp; 20mg Citalopram taken orally one time per day 0r 50mg Bupropion &amp; 10mg Citalopram taken orally one time per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupropion &amp; Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100mg Bupropion &amp; Placebo taken orally one time per day or 50mg Bupropion &amp; Placebo taken orally one time per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &amp; Citalopram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo &amp; 20mg Citalopram taken orally one time per day or Placebo &amp; 10mg Citalopram taken orally one time per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &amp; Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo &amp; Placebo taken orally one time per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion &amp; Citalopram</intervention_name>
    <arm_group_label>Bupropion &amp; Citalopram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion &amp; Placebo</intervention_name>
    <arm_group_label>Bupropion &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo &amp; Citalopram</intervention_name>
    <arm_group_label>Placebo &amp; Citalopram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo &amp; Placebo</intervention_name>
    <arm_group_label>Placebo &amp; Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: N/A -

        Exclusion Criteria: N/A

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Drew Kern, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 4, 2013</lastchanged_date>
  <firstreceived_date>October 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
